By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the market closed Monday second-quarter revenue growth of 162 percent, and said that it is seeking a new CEO for the firm, which completed its first quarter since going public in the US.

The California-based molecular diagnostics firm, which formerly was based in the UK and known as Osmetech, brought in total revenues of $650,712 for the three months ended June 30, compared to $248,568 for the second quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.